Constipation - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 121
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CFCB48D528DEN
Leaflet:

Download PDF Leaflet

Constipation - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Constipation - Pipeline Review, H2 2016’, provides an overview of the Constipation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Constipation
  • The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects
  • The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Constipation
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Constipation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Constipation Overview
Therapeutics Development
Pipeline Products for Constipation - Overview
Pipeline Products for Constipation - Comparative Analysis
Constipation - Therapeutics under Development by Companies
Constipation - Therapeutics under Investigation by Universities/Institutes
Constipation - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Constipation - Products under Development by Companies
Constipation - Products under Investigation by Universities/Institutes
Constipation - Companies Involved in Therapeutics Development
AlbireoPharma
Ardelyx, Inc.
Astellas Pharma Inc.
Braintree Laboratories, Inc.
CJ HealthCare Corp.
EA Pharma Co Ltd
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Motus Therapeutics Inc
NGM Biopharmaceuticals, Inc.
RaQualia Pharma Inc.
Sanwa Kagaku Kenkyusho Co., Ltd.
Shire Plc
SK Biopharmaceuticals Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Torrent Pharmaceuticals Limited
Yuhan Corporation
Constipation - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
5-BIOP - DRUG PROFILE
Product Description
Mechanism Of Action
R&D Progress
AJG-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7663 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-14199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KWA-0711 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transilon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation - Dormant Projects
Constipation - Product Development Milestones
Featured News & Press Releases
Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review
May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 22, 2016: Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
May 21, 2016: Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016
May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Apr 19, 2016: Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation
Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide)
Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
Jan 29, 2016: Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation
Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Dec 08, 2015: Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Constipation, H2 2016
Number of Products under Development for Constipation - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Constipation - Pipeline by AlbireoPharma, H2 2016
Constipation - Pipeline by Ardelyx, Inc., H2 2016
Constipation - Pipeline by Astellas Pharma Inc., H2 2016
Constipation - Pipeline by Braintree Laboratories, Inc., H2 2016
Constipation - Pipeline by CJ HealthCare Corp., H2 2016
Constipation - Pipeline by EA Pharma Co Ltd, H2 2016
Constipation - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
Constipation - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Constipation - Pipeline by Motus Therapeutics Inc, H2 2016
Constipation - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
Constipation - Pipeline by RaQualia Pharma Inc., H2 2016
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
Constipation - Pipeline by Shire Plc, H2 2016
Constipation - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Constipation - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Constipation - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Constipation - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016
Constipation - Pipeline by Synthetic Biologics, Inc., H2 2016
Constipation - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
Constipation - Pipeline by Yuhan Corporation, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Constipation - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Constipation, H2 2016
Number of Products under Development for Constipation - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AlbireoPharma
Ardelyx, Inc.
Astellas Pharma Inc.
Braintree Laboratories, Inc.
CJ HealthCare Corp.
EA Pharma Co Ltd
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Motus Therapeutics Inc
NGM Biopharmaceuticals, Inc.
RaQualia Pharma Inc.
Sanwa Kagaku Kenkyusho Co., Ltd.
Shire Plc
SK Biopharmaceuticals Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Torrent Pharmaceuticals Limited
Yuhan Corporation
Skip to top


Ask Your Question

Constipation - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: